{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:35:46Z","timestamp":1772120146131,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T00:00:00Z","timestamp":1757635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T00:00:00Z","timestamp":1757635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["15\/130\/94"],"award-info":[{"award-number":["15\/130\/94"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Patient"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s40271-025-00771-5","type":"journal-article","created":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T17:49:56Z","timestamp":1757699396000},"page":"121-129","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Which Factors Influence Decisions to Withdraw from Eculizumab: A Qualitative Study of Patients Diagnosed with aHUS"],"prefix":"10.1007","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5191-5804","authenticated-orcid":false,"given":"Jan","family":"Lecouturier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3743-2371","authenticated-orcid":false,"given":"Neil","family":"Sheerin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,12]]},"reference":[{"issue":"16","key":"771_CR1","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1182\/blood.2022018833","volume":"142","author":"V Brocklebank","year":"2023","unstructured":"Brocklebank V, Walsh PR, Smith-Jackson K, Hallam TM, Marchbank KJ, Wilson V, et al. Atypical hemolytic uremic syndrome in the era of terminal complement inhibition: an observational cohort study. Blood. 2023;142(16):1371\u201386.","journal-title":"Blood"},{"key":"771_CR2","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2147\/CLEP.S245642","volume":"12","author":"K Yan","year":"2020","unstructured":"Yan K, Desai K, Gullapalli L, Druyts E, Balijepalli C. Epidemiology of atypical hemolytic uremic syndrome: a systematic literature review. Clin Epidemiol. 2020;12:295\u2013305.","journal-title":"Clin Epidemiol"},{"issue":"1","key":"771_CR3","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ekir.2022.11.006","volume":"8","author":"M Noris","year":"2023","unstructured":"Noris M, Remuzzi G. Eculizumab \u2013 every fifteen days forever? Kidney Int Rep. 2023;8(1):4\u20137.","journal-title":"Kidney Int Rep"},{"issue":"23","key":"771_CR4","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","volume":"368","author":"CM Legendre","year":"2013","unstructured":"Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, et al. Terminal complement inhibitor eculizumab in atypical hemolytic\u2013uremic syndrome. N Engl J Med. 2013;368(23):2169\u201381.","journal-title":"N Engl J Med"},{"key":"771_CR5","unstructured":"National Institute for Health and Care Excellence. Nice guidance. Eculizumab for treating atypical haemolytic uraemic syndrome. London: NICE; 2015. https:\/\/www.nice.org.uk\/guidance\/hst1\/documents\/atypical-haemolytic-uraemic-syndrome-ahus-eculizumab-evalution-consultation-document-2"},{"issue":"9","key":"771_CR6","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1111\/ajt.14426","volume":"17","author":"LA McNamara","year":"2017","unstructured":"McNamara LA, Topaz N, Wang X, Hariri S, Fox L, MacNeil JR. High risk for invasive meningococcal disease among patients receiving eculizumab (Soliris) despite receipt of meningococcal vaccine. Am J Transplant. 2017;17(9):2481\u20134.","journal-title":"Am J Transplant"},{"issue":"3","key":"771_CR7","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1182\/bloodadvances.2021006416","volume":"7","author":"AA Acosta-Medina","year":"2023","unstructured":"Acosta-Medina AA, Moyer AM, Go RS, et al. Complement gene variant effect on relapse of complement-mediated thrombotic microangiopathy after eculizumab cessation. Blood Adv. 2023;7(3):340\u201350. https:\/\/doi.org\/10.1182\/bloodadvances.2021006416.","journal-title":"Blood Adv"},{"issue":"6","key":"771_CR8","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.25640","volume":"14","author":"RK Dhanoa","year":"2022","unstructured":"Dhanoa RK, Selvaraj R, Shoukrie SI, Zahra A, Malla J, Selvamani TY, et al. Eculizumab\u2019s unintentional mayhem: a systematic review. Cureus. 2022;14(6):e25640. https:\/\/doi.org\/10.7759\/cureus.25640.","journal-title":"Cureus"},{"issue":"4","key":"771_CR9","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1053\/j.ajkd.2014.01.434","volume":"64","author":"G Ardissino","year":"2014","unstructured":"Ardissino G, Testa S, Possenti I, Tel F, Paglialonga F, Salardi S, et al. Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases. Am J Kidney Dis. 2014;64(4):633\u20137.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"771_CR10","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1053\/j.ajkd.2015.04.010","volume":"66","author":"G Ardissino","year":"2015","unstructured":"Ardissino G, Possenti I, Tel F, Testa S, Salardi S, Ladisa V. Discontinuation of eculizumab treatment in atypical hemolytic uremic syndrome: an update. Am J Kidney Dis. 2015;66(1):172\u20133.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"771_CR11","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ekir.2022.10.013","volume":"8","author":"RN Bouwmeester","year":"2023","unstructured":"Bouwmeester RN, Duineveld C, Wijnsma KL, Bemelman FJ, van der Heijden JW, van Wijk JA, et al. Early eculizumab withdrawal in patients with atypical hemolytic uremic syndrome in native kidneys is safe and cost-effective: results of the CUREiHUS study. Kidney Int Rep. 2023;8(1):91\u2013102.","journal-title":"Kidney Int Rep."},{"key":"771_CR12","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s40620-016-0288-3","volume":"30","author":"JV Walle","year":"2017","unstructured":"Walle JV, Delmas Y, Ardissino G, et al. Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment. J Nephrol. 2017;30:127. https:\/\/doi.org\/10.1007\/s40620-016-0288-3.","journal-title":"J Nephrol"},{"issue":"3","key":"771_CR13","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1002\/acr.24129","volume":"73","author":"DB Horton","year":"2021","unstructured":"Horton DB, Salas J, Wec A, Kohlheim M, Kapadia P, Beukelman T, et al. Making decisions about stopping medicines for well-controlled juvenile idiopathic arthritis: a mixed-methods study of patients and caregivers. Arthritis Care Res Hoboken. 2021;73(3):374\u201385.","journal-title":"Arthritis Care Res Hoboken"},{"key":"771_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41927-019-0070-y","volume":"3","author":"KF Baker","year":"2019","unstructured":"Baker KF, Isaacs JD, Thompson B. \u201cLiving a normal life\u201d: a qualitative study of patients\u2019 views of medication withdrawal in rheumatoid arthritis. BMC Rheumatol. 2019;3:1\u20138. https:\/\/doi.org\/10.1186\/s41927-019-0070-y.","journal-title":"BMC Rheumatol."},{"issue":"9","key":"771_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-054536","volume":"12","author":"S Dunn","year":"2022","unstructured":"Dunn S, Brocklebank V, Bryant A, Carnell S, Chadwick TJ, Johnson S, et al. Safety and impact of eculizumab withdrawal in patients with atypical haemolytic uraemic syndrome: protocol for a multicentre, open-label, prospective, single-arm study. BMJ Open. 2022;12(9):e054536.","journal-title":"BMJ Open"},{"key":"771_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2025.101392","volume":"56","author":"A Bryant","year":"2025","unstructured":"Bryant A, Lecouturier J, Orozco-Leal G, Brocklebank V, Carnell S, Chadwick T, et al. Eculizumab withdrawal and monitoring in atypical haemolytic uraemic syndrome (SETS aHUS): a multicentre, open label, prospective, single arm trial. Lancet Reg Health Eur. 2025;56:101392. https:\/\/doi.org\/10.1016\/j.lanepe.2025.101392.","journal-title":"Lancet Reg Health Eur"},{"key":"771_CR17","doi-asserted-by":"crossref","unstructured":"Orozco-Leal G, Vale L, Oluboyede Y, Bryant A, Weetman C, Kennedy C, Kavanagh D, Wong E, Lecouturier J, Woodward L, Brocklebank V, Johnson S, Dunn S, Chadwick T, Sheerin NS. A strategy of eculizumab treatment withdrawal with disease monitoring is cost-effective compared to lifelong treatment for eligible atypical haemolytic uraemic syndrome patients: an economic evaluation of the SETS aHUS trial. Nephrol Dialysis Transplant 2025.","DOI":"10.1101\/2025.07.14.25331491"},{"key":"771_CR18","volume-title":"Qualitative methods for health research","author":"J Green","year":"2014","unstructured":"Green J, Thorogood N. Qualitative methods for health research. 3rd ed. London: SAGE; 2014.","edition":"3"},{"key":"771_CR19","volume-title":"Strategies of qualitative inquiry","year":"2014","unstructured":"Denzin NK, Lincoln YS, editors. Strategies of qualitative inquiry. 4th ed. California: SAGE; 2014.","edition":"4"},{"issue":"1","key":"771_CR20","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1177\/1468794104041110","volume":"4","author":"JE Sturges","year":"2004","unstructured":"Sturges JE, Hanrahan KJ. Comparing telephone and face-to-face qualitative interviewing: a research note. Qual Res. 2004;4(1):107\u201318.","journal-title":"Qual Res"},{"issue":"1","key":"771_CR21","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/qjmed\/hcv082","volume":"109","author":"NS Sheerin","year":"2016","unstructured":"Sheerin NS, Kavanagh D, Goodship TH, Johnson S. A national specialized service in England for atypical haemolytic uraemic syndrome-the first year\u2019s experience. QJM. 2016;109(1):27\u201333. https:\/\/doi.org\/10.1093\/qjmed\/hcv082.","journal-title":"QJM"},{"key":"771_CR22","volume-title":"Methods in educational research: From theory to practice","author":"MG Lodico","year":"2010","unstructured":"Lodico MG, Spaulding DT, Voegtle KH. Methods in educational research: From theory to practice. John Wiley & Sons; 2010."},{"key":"771_CR23","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1023\/A:1020909529486","volume":"36","author":"H Boeije","year":"2002","unstructured":"Boeije H. A purposeful approach to the constant comparative method in the analysis of qualitative interviews. Qual Quant. 2002;36:391\u2013409.","journal-title":"Qual Quant"},{"issue":"9","key":"771_CR24","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1002\/cam4.2940","volume":"9","author":"K Ala-Leppilampi","year":"2020","unstructured":"Ala-Leppilampi K, Baker NA, McKillop C, Butler MO, Siu LL, Spreafico A, et al. Cancer patients\u2019 experiences with immune checkpoint modulators: a qualitative study. Cancer Med. 2020;9(9):3015\u201322.","journal-title":"Cancer Med"},{"key":"771_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.710518","volume":"12","author":"R Janssens","year":"2021","unstructured":"Janssens R, Arnou R, Schoefs E, Petrocchi S, Cincidda C, Ongaro G, et al. Key determinants of health-related quality of life among advanced lung cancer patients: a qualitative study in Belgium and Italy. Front Pharmacol. 2021;12:710518.","journal-title":"Front Pharmacol"},{"issue":"7","key":"771_CR26","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1016\/j.ekir.2024.04.047","volume":"9","author":"RN Bouwmeester","year":"2024","unstructured":"Bouwmeester RN, Engel LJ, Altena W, Renette C, van Daelen C, van Kempen E, et al. Living with atypical hemolytic uremic syndrome in the Netherlands: patient and family perspective. Kidney Int Rep. 2024;9(7):2189\u201397. https:\/\/doi.org\/10.1016\/j.ekir.2024.04.047.","journal-title":"Kidney Int Rep"},{"issue":"9","key":"771_CR27","doi-asserted-by":"publisher","first-page":"e230036","DOI":"10.57264\/cer-2023-0036","volume":"12","author":"TJ Mauch","year":"2023","unstructured":"Mauch TJ, Chladek MR, Cataland S, Chaturvedi S, Dixon BP, Garlo K, et al. Treatment preference and quality of life impact: ravulizumab vs eculizumab for atypical hemolytic uremic syndrome. J Comp Eff Res. 2023;12(9):e230036. https:\/\/doi.org\/10.57264\/cer-2023-0036.","journal-title":"J Comp Eff Res"},{"issue":"1","key":"771_CR28","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1186\/s12882-024-03770-0","volume":"25","author":"E Germeni","year":"2024","unstructured":"Germeni E, Cooper J, Briggs A, Laurence J. Treatment discontinuation in adults with atypical hemolytic uremic syndrome (aHUS): a qualitative study of international experts\u2019 perspectives with associated cost-consequence analysis. BMC Nephrol. 2024;25(1):411. https:\/\/doi.org\/10.1186\/s12882-024-03770-0.","journal-title":"BMC Nephrol"}],"container-title":["The Patient - Patient-Centered Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-025-00771-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40271-025-00771-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-025-00771-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T21:02:51Z","timestamp":1768165371000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40271-025-00771-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,12]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["771"],"URL":"https:\/\/doi.org\/10.1007\/s40271-025-00771-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2025.07.21.25331504","asserted-by":"object"}]},"ISSN":["1178-1653","1178-1661"],"issn-type":[{"value":"1178-1653","type":"print"},{"value":"1178-1661","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,12]]},"assertion":[{"value":"2 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by the National Institute for Health and Care Research (NIHR) (Grant 15\/130\/94) Health Technology Assessment programme. The views expressed in this publication are those of the author(s) and not necessarily those of the NIHR.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"A favourable ethical opinion was obtained from North East-Tyne & Wear South Research Ethics (18\/NE\/0113).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"It is not possible for the data from this study to be made available.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"JL and NS devised the study design and the topic of exploration for the qualitative component. JL conducted the interviews, analysed the data, and drafted the manuscript. NS reviewed and contributed to the final manuscript.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}